Abstract 6192: Disparities in cancer-causing substance use in trans and gender diverse communities: Canadian population-based data

This study utilized data from the Canadian Community Health Survey, which is an annual, population-based, cross-sectional survey that covers topics such as physical and mental health, chronic health conditions, and lifestyle behaviors. The 2019 and 2020 Canadian Community Health Survey was pooled, and a gender modality variable was derived by comparing sex assigned at birth and gender identity. The gender modality variable was classified into two categories: 1) Cisgender (CG) people who had a sex assigned at birth that aligned with their gender identity, and 2) Trans and gender diverse (TGD) people who had a sex assigned at birth that differed from their gender identity. Both complete case and imputed datasets were used in this analysis. For imputed datasets, multiple imputation with chained equations was used to handle missing data. Survey and bootstrap weights were applied to unadjusted and adjusted logistic regression analyses, where gender modality was the explanatory variable, and substance use types were the dependent variables. This study found that there were no significant differences in alcohol, smoking, and e-cigarettes use by gender modality in both adjusted and unadjusted models. However, TGD people had higher odds of daily or almost daily cannabis use, compared to CG people, while adjusting for covariates (adjusted odds ratio (aOR): 3.7, 95% confidence interval (CI): 1.7-7.8). Future research should determine the level of knowledge in TGD communities for cancer-related implications of cannabis use. In addition, the acceptance and feasibility of harm reduction programs tailored for TGD communities, should be explored. Citation Format: Ace Chan, Hannah Kia, Travis Salway, Trevor Dummer. Disparities in cancer-causing substance use in trans and gender diverse communities: Canadian population-based data [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6192.